[1] Zhu RX, Seto WK, Lai CL, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver, 2016, 10:332-339. [2] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018, 6:e555-e567. [3] 闫伟伟, 黄昂, 李永纲, 等. CD34与CD117在人肝癌组织中的表达及其临床意义. 中华肝脏病杂志, 2011, 19. [4] Paschoal JP, Bernardo V, Canedo NH, et al. Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immuno-expression. BMC Cancer,2014,14:72. [5] Cui DJ, Wu Y, Wen DH. CD34, PCNA and CK19 expressions in AFP- hepatocellular carcinoma. Eur Rev Med Pharmacol Sci,2018,22: 5200-5205. [6] 刘明东,余宗阳,赵忠全,等.PD-L1、Ki67 预测非小细胞肺癌术后进展的研究.现代肿瘤医学,2017,25:885-889. [7] 胡志超,金浩生,林叶,等.Ki67和 Glut1在肝细胞癌中的表达及预后意义.肝脏,2015:393-396. [8] Luo Y, Ren F, Liu Y, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med, 2015, 8:10235-10247. [9] Yu YH, Morales J, Feng L, et al. CD147 and Ki-67 overex-pression confers poor prognosis in squamous cell carcinoma of oral tongue: A tissue microarray study. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119:553-565. [10] 杨晓珍, 龙江, 赵鹏, 等. 肝癌分化程度与肝脏CT强化特点及CD34、p53、GPC3、CK19、Ki-67表达的关系. 癌症进展, 2018, 16:84-87. |